Skip to content
10-K

Annual Report

ADMA BIOLOGICS, INC. ADMA

0001140361-25-009257

← back to feed
Filed
Mar 18, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 10, 2025 237.62M sh
Cash And Equivalents FY 2024 · Dec 31, 2023 $51.35M
Current Liabilities FY 2024 · Dec 31, 2023 $49.81M
Total Liabilities FY 2024 · Dec 31, 2023 $193.98M
Current Assets FY 2024 · Dec 31, 2023 $257.01M
Shares Diluted FY 2024 · Dec 31, 2022 197.87M sh
Capex restated FY 2024 · Dec 31, 2022 $13.91M
Operating Cash Flow restated FY 2024 · Dec 31, 2022 −$59.51M
Total Assets restated FY 2024 · Dec 31, 2022 $348.46M
Eps Diluted FY 2024 · Dec 31, 2022 −$0.33
Eps Basic FY 2024 · Dec 31, 2022 −$0.33
Sga Expense restated FY 2024 · Dec 31, 2022 $52.46M
Rd Expense restated FY 2024 · Dec 31, 2022 $3.61M
Rd Expense restated FY 2024 · Apr 1, 2019 $1M
Net Income restated FY 2024 · Dec 31, 2022 −$65.9M
Operating Income restated FY 2024 · Dec 31, 2022 −$39.37M
Gross Profit restated FY 2024 · Dec 31, 2022 $35.27M
Cost Of Revenue restated FY 2024 · Dec 31, 2022 $118.82M
Revenue restated FY 2024 · Dec 31, 2022 $154.08M
Stockholders Equity restated FY 2024 · Dec 31, 2021 $141.17M